START Program for ADHD
(START Trial)
Trial Summary
What is the purpose of this trial?
The randomized control trial (RCT) study includes 2 aims; one being to test whether START increases access to treatment for ADHD. Investigators believe the intervention group will demonstrate improved treatment engagement and access to all treatments compared to controls. The second aim is to explore whether START leads to functional improvements across home, social and academic domains for the child and family. Investigators believe the intervention group will show better functioning including improved family and peer relationships and reduced parent stress compared to controls. Before taking part in our study all participants will undergo a psychiatric evaluation. Eligible participants will be randomized to START while controls receive a pamphlet with ADHD information. Students and staff with related experience who are not mental health professionals will be trained to deliver START. START includes 6 modules, typically delivered over 6 sessions.
Do I have to stop taking my current medications for the trial?
The trial does not specify if you need to stop taking your current medications. However, if you have been treated for ADHD in the past 12 months, you are not eligible to participate.
What data supports the idea that START Program for ADHD is an effective treatment?
The available research shows that patients who received combined treatment, which may include programs like the START Program for ADHD, were significantly more likely to improve compared to those who received only medication or psychological treatment alone. Specifically, 65.5% of patients improved with combined treatment, compared to 54.4% with medication alone and 53.4% with psychological treatment alone. This suggests that the START Program, as part of a combined approach, can be an effective treatment for ADHD.12345
What safety data is available for the START Program for ADHD treatment?
The provided research does not directly mention the START Program for ADHD or its safety data. However, it discusses the safety and adverse events associated with ADHD medications in general. The studies highlight the prevalence of adverse events, management strategies, and monitoring methods for ADHD treatments, including stimulants like methylphenidate. These findings suggest that while ADHD medications are effective, they can have side effects such as nausea, dizziness, and sleep disturbances, and require careful monitoring and management.678910
Is the START treatment for ADHD promising?
Eligibility Criteria
This trial is for children aged 6-12 with a new or previously untreated ADHD diagnosis, confirmed by the study's psychiatrist. They must be able to understand and follow the study in English. Children treated for other conditions can join if it wasn't for ADHD.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- SupporT for ADHD and Related Treatment
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ann & Robert H Lurie Children's Hospital of Chicago
Lead Sponsor